Intravitreal conbercept injection for neovascular age-related macular degeneration
To evaluate the efficacy and safety of intravitreal injection of conbercept in patients with neovascular age-related macular degeneration (AMD). Retrospective review of 66 eyes of 63 patients with neovascular AMD. All patients received 0.5 mg intravitreal injections of conbercept monthly for 3 conse...
Saved in:
Published in | International journal of ophthalmology Vol. 12; no. 2; pp. 252 - 257 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
China
International Journal of Ophthalmology Press
18.02.2019
Press of International Journal of Ophthalmology (IJO PRESS) |
Subjects | |
Online Access | Get full text |
ISSN | 2222-3959 2227-4898 |
DOI | 10.18240/ijo.2019.02.11 |
Cover
Loading…
Summary: | To evaluate the efficacy and safety of intravitreal injection of conbercept in patients with neovascular age-related macular degeneration (AMD).
Retrospective review of 66 eyes of 63 patients with neovascular AMD. All patients received 0.5 mg intravitreal injections of conbercept monthly for 3 consecutive months, and then
treatment was performed. The changes of best-corrected visual acuity (BCVA) and central macular thickness (CMT) were observed before and after treatments. Minimum follow-up time was 12mo. SPSS 22.0 statistical software was used for statistical analysis.
The mean BCVA and CMT of 66 eyes (63 patients) were 1.11±0.60, 533.20±219.95 µm at baseline, and were 0.68±0.38, 310.28±125.60 µm at 3mo. No subjects were lost during the first three months, the improvements were all significantly (
<0.05). During the whole follow-up time of 12mo, 15 subjects (18 eyes) were lost. The mean BCVA and CMT of the rest 48 eyes with the follow-up time at least 1y were 0.83±0.46 and 547.59±196.77 µm at baseline, after 3mo and 12mo of conbercept injections became 0.55±0.41, 318.24±141.29 µm and 0.55±0.51, 333.87±173.25 µm. The differences were significant (
<0.05). No serious complications were observed.
Intravitreal injection of conbercept appears to significantly improve visual acuity and anatomical outcomes in patients with neovascular AMD, no serious adverse reactions and complications are observed. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Co-first authors: Bing-Hui Wu and Bing Wang |
ISSN: | 2222-3959 2227-4898 |
DOI: | 10.18240/ijo.2019.02.11 |